Arbutus生物制药 ABUS 深 沪
已收盘 08-01 16:00:00 美东时间
3.27
-0.010
-0.30%
华盛通- 最 高3.39
- 今 开3.27
- 成交量 55.47万股
- 最 低 3.27
- 昨 收 3.28
- 总市值 6.28亿
- 52周最高 4.725
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 2.705
- 委 比 53.16%
- 总股本 1.92亿
- 历史最高 31.48
- 量 比 0.93
- 振 幅 3.66%
- 历史最低 0.821
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 14,000 restricted stock units to two new hires under its 2022 Inducement Plan, vesting over four years. The company, focused on immune-mediated dermatology, aims to innovate treatments for skin diseases.
07-03 20:00
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
The latest update is out from Arbutus Biopharma ( ($ABUS) ). On June 20, 2025, ...
06-25 19:59
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus and Qilu Pharmaceutical have mutually terminated their 2021 strategic partnership for imdusiran in Greater China, with Arbutus regaining global rights. Arbutus launched a Scientific Advisory Board with leading experts in chronic hepatitis B to guide its cHBV pipeline evaluation. Imdusiran has achieved functional cure in 8 patients across Phase 2a trials.
06-25 11:30
Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 30 percent decrease over losses of $(0.10) per share from the
05-14 19:36
Arbutus's Imdusiran Plus VTP-300 And Low-Dose Nivolumab Achieve HBsAg Loss And Seroconversion In cHBV Patients, New Phase 2a Data Reveal At EASL 2025
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumabIn a Phase 1a/1b clinical trial,
05-07 15:10
超百款新车、千家企业齐聚“上海滩”！2025上海车展掀起“智电”浪潮 这场展会还藏着未来发展“生死密码”
每经记者 黄辛旭每经编辑 孙磊 2025上海车展，为竞争激烈且复杂的国内车市指明了方向。 4月23日，第二十一...
04-23 22:59
中国汽车市场一周行业信息快报——2025年4月第1期
进入4月，随着多地开启春季车展，车市竞争开始进入白热化阶段，各大车企争先推出重磅新车的同时，它们的发展策略同样值得关注。下面，就来盘点一下上周汽车行业都发生了哪...
04-07 18:37
美股大行评级 | 潜在涨幅686.94%！Sensei Biotherapeutics获Oppenheimer升目标价至4美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112661771769712640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Sensei Biotherapeutics(SNSE)"跑赢大市"评级，目标价从3.5美元升至4美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至
03-29 18:13
Arbutus announces a 57% workforce reduction
Along with its Q4 2024 financials on Thursday, antiviral developer Arbutus Biopharma (NASDAQ:ABUS) announced plans to reduce its workforce by 57% as part of a broader restructuring program, which also...
03-27 21:03
